Navigation Links
Drug may prolong organ life in noncompliant kidney transplant patients
Date:5/30/2008

New research from the University of California, San Diego Department of Medicine, Division of Nephrology, shows that the anti-rejection drug sirolimus (brand name Rapamune) may help prolong the clinical benefit of transplanted kidneys and delay rejection, especially in patients who do not regularly take their prescribed medications (are "non-compliant"). While the transplant field has been highly successful at reducing rejection and graft loss in the first year, post-transplant, reducing risk for graft rejection in the long-term has proved more difficult.

The findings are being presented at the 2008 American Transplant Congress (ATC), in Toronto on Saturday, May 31, 2008, by Cheri Ye, M.D., who was mentored by Robert Steiner, M.D., professor of medicine, and Director of Transplant Nephrology.

"No one is perfect at taking medications," explained Steiner. "But missing doses of immunosuppression, or not taking full doses each day, will bring about gradual rejection of kidney transplants that is almost impossible to detect in its early stages. Long acting drugs like sirolimus may help with this problem."

A team of five UC San Diego investigators reported a careful assessment of immune function at "trough" levels (lowest daily levels) of the three most commonly used immunosuppressive drugs, using an assay (ImmuKnow/ Cylex) designed specifically to measure the degree of immunosuppression at any given time. Lower "mitogenic response" meant better immunosuppression and more protection from rejection. On average, the participants, 160 kidney transplant patients, were 6.4 years out from their transplant.

At these trough levels of drug in the blood stream, the assay demonstrated that sirolimus caused a significantly lower level of mitogenic response, and results appeared to be stable in individual patients over time.

"At least half of transplanted kidneys are lost through chronic graft rejection, usually within 10 years. When patients do not have those rejection problems, they can go for 20 to 30 years before kidney rejection or other serious problems. This is an especially important issue now because of our nationwide donor-organ shortage," said coauthor, David Perkins, M.D., Ph.D., professor of medicine & surgery, and Director of Research for Transplantation.

"This study was not commercially funded," added Steiner. "We just wanted to confirm what we suspected from experience in our transplant clinic, where we focus on compliance in many ways to help our patients keep their kidneys functioning well. We showed that when the daily dose is wearing off and another dose is due to be taken, patients taking sirolimus could be more protected against rejection than other commonly used agents."

The assay used is the only commercially available of its kind, and potentially valuable, but researchers emphasized that experience and understanding of it is limited.

"Our ATC abstract is a report of clinical experience, but real progress is often made at the level of basic science. My laboratory is studying this intensively at a basic level in several ways, including looking at the genetics associated with various responses to the assay," said Perkins.

The researchers believe that this new study may help develop tools to monitor patients in the long-term, and also contribute to a protocol for using sirolimus in less compliant patients. Steiner pointed out that, "The best results will occur if we prevent rejection, because once rejection is established the threat to graft survival is much greater, no matter what we do."


'/>"/>

Contact: Kim Edwards
kedwards@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
2. LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon
3. Token resuscitation attempts on hopelessly ill patients prolong suffering
4. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival for AML Patients Treated with Ceplene(TM) + IL-2
6. Treating oft ignored non-cancer health issues after cancer diagnosis prolongs survival
7. Treatment capitalizes on unique qualities of radioisotope to prolong lives of brain tumor patients
8. AACN Concerned That the Presidents FY 2009 Budget Request Will Prolong the Nursing and Nurse Faculty Shortage
9. California Small Business Association Condemns California Nurses Associations Decision to Call Prolonged Strike at Hospitals Throughout Northern California
10. Prolonged Fasting Boosts Risk of Rare Stroke
11. Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing ... their videos a whole new perspective by using the title layers in ProSlice ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
Breaking Medicine Technology: